<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03320642</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-119/GRAVITAS-119</org_study_id>
    <nct_id>NCT03320642</nct_id>
  </id_info>
  <brief_title>GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease</brief_title>
  <official_title>GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact and safety of itacitinib in combination&#xD;
      with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of&#xD;
      graft-versus-host-disease (GVHD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated by sponsor&#xD;
  </why_stopped>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with hematologic recovery when itacitinib is added to GVHD prophylaxis treatment</measure>
    <time_frame>Day 28</time_frame>
    <description>Hematologic recovery defined as demonstrating both neutrophil recovery (ANC ≥ 500/mm^3 for 3 consecutive measurements) and platelet recovery (platelet count ≥ 20,000/mm^3 with no requirement for platelet transfusion in the preceding 3 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GVHD relapse-free survival rate</measure>
    <time_frame>Days 100, 180 and 365</time_frame>
    <description>Defined as the proportion of subjects who do not experience Grade III-IV acute GVHD (aGVHD), chronic GVHD (cGVHD) requiring systemic therapy, malignancy relapse or progression, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Defined as the interval between enrollment and malignancy relapse or progression, or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Defined as the proportion of subjects who die due to causes other than malignancy relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to neutrophil and platelet engraftment</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Defined as the median time to achieve neutrophil and platelet engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who achieve neutrophil and platelet engraftment</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Defined as the median time to achieve engraftment and hematologic recovery at prespecified time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are diagnosed with Grade II-IV aGVHD, by each grade and by Grade III/IV</measure>
    <time_frame>Days 100 and Days 180</time_frame>
    <description>Measured to assess the incidence of aGVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are diagnosed with cGVHD by grade (mild, moderate, or severe)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Measured to assess the incidence of cGVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Defined as the proportion of subjects who demonstrate an infection and/or cytomegalovirus reactivation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Defined as the interval between enrollment and death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with Grade 3-5 treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 200 days</time_frame>
    <description>TEAE is defined as either an adverse event (AE) reported for the first time or worsening of a pre-existing condition after the first dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itacitinib in combination with a CNI-based intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Itacitinib administered orally once daily at the protocol-defined dose.</description>
    <arm_group_label>Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin inhibitor</intervention_name>
    <description>The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.</description>
    <arm_group_label>Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute leukemia, chronic myelogenous leukemia, or myelodysplasia with no&#xD;
             circulating blasts and &lt; 5% blasts in the bone marrow.&#xD;
&#xD;
          -  Subjects with non-Hodgkin lymphoma, including but not limited to chronic lymphocytic&#xD;
             leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B cell,&#xD;
             or mantle cell lymphoma must have chemosensitive disease at time of transplant.&#xD;
             Subjects with Hodgkin lymphoma with chemosensitive disease at the time of transplant.&#xD;
&#xD;
          -  Must be candidates for reduced-intensity conditioning regimens.&#xD;
&#xD;
          -  Must be candidates for peripheral blood stem cell transplants.&#xD;
&#xD;
          -  Karnofsky Performance Status score ≥ 70% or Eastern Cooperative Oncology Group&#xD;
             Performance Status score of 0 to 2.&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 40 mL/min measured or&#xD;
             calculated by Cockcroft-Gault equation.&#xD;
&#xD;
          -  Be willing to avoid pregnancy or fathering children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has previously received an allogenic hematopoietic stem cell transplant.&#xD;
&#xD;
          -  Presence of an active uncontrolled infection.&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires&#xD;
             treatment or at risk for HBV reactivation.&#xD;
&#xD;
          -  Prior malignancies.&#xD;
&#xD;
          -  Severe organ dysfunction.&#xD;
&#xD;
          -  Prior treatment with a JAK inhibitor or with an investigational agent, device, or&#xD;
             procedure within 21 days of enrollment.&#xD;
&#xD;
          -  Currently breastfeeding.&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to any of the study medications.&#xD;
&#xD;
          -  Receipt of live (including attenuated) vaccines during the study, or anticipation of&#xD;
             need for such a vaccine during the study.&#xD;
&#xD;
          -  History of primary idiopathic myelofibrosis or any severe marrow fibrosis that would&#xD;
             prolong neutrophil engraftment to &gt; 28 days after transplant.&#xD;
&#xD;
          -  Post-transplant maintenance therapy for the hematologic malignancy or plans to&#xD;
             initiate maintenance therapy during study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Morariu-Zamfir, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anschutz Cancer Pavilion - University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru de Lille Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Vandoeuvre-Les-Nancy, Hopital Brabois</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii (Presidio Papa Giovanni Xxiii)</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo Di Monza</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute leukemia</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>myelodysplasia</keyword>
  <keyword>chronic lymphocytic leukemia/small lymphocytic lymphoma</keyword>
  <keyword>follicular</keyword>
  <keyword>marginal zone</keyword>
  <keyword>diffuse large B-cell</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>Janus kinase inhibitor</keyword>
  <keyword>graft-versus-host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

